|
**Overview**: Mitochondrial Antibody IFA Panel**Introduction**: The Mitochondrial Antibody IFA Panel is a diagnostic tool designed to screen for primary biliary cholangitis using serum samples. In India, PBC (autoimmune liver disease) affects ~1 in 10,000-20,000 women (middle age), with antimitochondrial antibodies (AMA) positive in >90 percent of cases, leading to cholestasis, fatigue, pruritus, and cirrhosis if untreated. High morbidity from under-testing in rural/low-SES women with unexplained elevated ALP/jaundice, limited immunofluorescence labs, delayed ursodeoxycholic acid (UDCA) therapy leading to progression to cirrhosis or HCC. Per hepatology practices aligned with ICMR and INASL guidelines, the test employs indirect immunofluorescence assay (IFA) for mitochondrial antibody and titer over 1-2 days with high specificity, valuable for early PBC diagnosis. This diagnostic falls under autoimmune screening and targets middle-aged women with cholestatic LFTs or fatigue, addressing accurate detection to guide UDCA and monitoring. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise AMA detection and reducing PBC complications. Its serum-based approach ensures reliable autoantibody visualization.**Other Names**: AMA IFA Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: AMA-IFA standard for PBC; in India, used in liver clinics.**Purpose**: The test assesses 2 parameters including mitochondrial antibody to guide PBC screening, detect AMA positivity, inform UDCA therapy.**Test Parameters**: 1. Mitochondrial Antibody, 2. IFA Titer.**Pretest Condition**: No fasting required; patients should report fatigue or cholestatic symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on LFTs, pruritus, family autoimmune history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected PBC including cirrhosis, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using IFA by trained personnel to ensure sterile technique, avoid artifacts, and report titer/pattern within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or interfering antibodies can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive AMA (titer ≥1:40) with M2 pattern strongly indicates PBC, necessitating specialist input.**Specialist Consultation**: Hepatologists should be consulted for management.**Additional Supporting Tests**: AMA-M2 ELISA, liver biopsy for confirmation.**Test Limitations**: IFA subjective; comprehensive approach required.**References**: Indian Journal of Gastroenterology 2024, Liver Autoimmune Studies India 2023. |
